Seth Ettenberg

Seth Ettenberg is a Strategic Advisor at Manifold Bio, and they have also served as the Chief Scientific Officer at Unum Therapeutics, Oncology Biotherapeutics Head at the Cambridge site of Novartis, and Lab Head and Project Leader at CuraGen Corp.

Ettenberg has been working in the field of oncology biotherapeutics for over 20 years. Seth started their career as a Project Leader at CuraGen Corp., where they worked on the development of new cancer treatments. In 2005, they joined Novartis Institutes for Biomedical Research (NIBR) as a Lab Head. During their time at NIBR, they made significant contributions to the development of oncology therapeutics. In 2009, they were promoted to Oncology Biotherapeutics Head at the Cambridge site of Novartis.

At Novartis, Ettenberg oversaw the development of several oncology drugs that are now approved by the FDA, including Afinitor and Tasigna. Under their leadership, the Cambridge site became one of the leading oncology research centers in the world. In 2014, they left Novartis to join Unum Therapeutics as Chief Scientific Officer.

At Unum Therapeutics, Ettenberg is responsible for the overall scientific direction and strategy of the company. Seth has built and managed a team of highly talented researchers who are working on the development of novel antibody-coupled cellular immunotherapies. These new therapies have the potential to transform cancer treatment

Seth Ettenberg graduated from Ithaca College with a degree in Molecular and Cell Biology. Seth then went on to obtain their Ph.D. from Uniformed Services University of the Health Sciences.